Global EconomyCNBC•1 min read•11/16/2026 (2h ago)

Novo says Wegovy injection lowers BMI and obesity rates in children in trial

Novo says Wegovy injection lowers BMI and obesity rates in children in trial
60-Word AI Digest

Novo says Wegovy injection lowers BMI and obesity rates in children in trial. Reporting by CNBC highlights major developments in this space as key stakeholders evaluate broader implications. Further data and contextual analysis are actively being published. Access the full coverage dispatch below for complete documentation.

Key Takeaways

  • Novo says Wegovy injection lowers BMI and obesity rates in children in trial
  • Wegovy is already approved to treat obesity in children ages 12 and older, but there are currently no approved medications for those under 12.
  • Click full coverage link below for the complete official dispatch.

Wegovy is already approved to treat obesity in children ages 12 and older, but there are currently no approved medications for those under 12.

Original Publisher Attribution

This summary was curated from CNBC.

Read Original on CNBC
Novo says Wegovy injection lowers BMI and obesity rates in children in trial — Loop60